关键词:

左卡尼汀, 急性ST段抬高型心肌梗死, 经皮冠状动脉介入治疗, 心肌保护

Abstract:

Objective To investigate the myocardial protective effect of L⁃carnitine in acute ST⁃segment elevation myocardial infarction（STEMI）after percutaneous coronary intervention（PCI）. Methods 96 patients with STEMI after PCI who had been treated during the period of March 2018 to March 2019 were selected. They were randomly assigned to receive either routine prognostic improvement therapies with anticoagulation and lipid regulation（basic group，48 patients），or the routine therapies plus levocarnitine（study group，48 patients）for 14 days. Cardiac troponin I（cTnI），creatine kinase isoenzyme（CK⁃MB），serum superoxide dismutase（SOD）， total antioxidant capacity（T ⁃AOC），left ventricular ejection fraction（LVEF），and 6 ⁃ minute walking distance were compared between the two groups before and after treatment，so was the major adverse cardiovascular events （MACE）within 3 months after PCI between the two groups. Results There were no significant differences in cTnI， CK ⁃MB，SOD，T ⁃AOC，LVEF value，and 6⁃minute walking distance between the two groups before treatment （P > 0.05）. After treatment，the contents of cTnI and CK ⁃MB declined in both groups，and the content of cTnI was lower in the study group than in the basic group（P < 0.05），while that of CK⁃MB was similar（P > 0.05）；the contents of SOD，T ⁃AOC，LVEF and 6min walking distance increased and they were higher in the study group than in the basic group（P < 0.05）. The total incidence of MACE within 3 months after PCI was lower in the study group than in the basic group（P < 0.05）. Conclusions Levocarnitine can reduce the contents of cTnI and CK⁃MB， increase the contents of SOD and T ⁃AOC，improve myocardial damage，increase the LVEF value and 6⁃minute walking distance，and lower the incidence of MACE in STEMI patients after PCI.

Key words:

L?carnitine, ST?segment elevation myocardial infarction, percutaneous coronary interven? tion, myocardial protection